Naiyer Rizvi describes how transformative immunotherapy has been for the care of NSCLC patients in the last 1-2 years. He explains how the advances in first and second-line treatment of Lung cancer are leading to clinical practice changes. He points out how a better understanding of selection criteria now allows us to predict which patients may benefit the most from new therapies with durable response. He gives an overview of current research and future treatment opportunities.

Oncology Meeting Resources

Major Sponsors

AstraZeneca Servier

Main Sponsors

Amgen Astellas Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo Genomic Health Inc. ipsen Lilly Oncology MSD Nutricia Roche